secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001193125-26-110767
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi gains FDA alignment on Phase 3 IPF-cough program; cash $188.3M
--------------------------------------------------------------------

- FDA alignment on Phase 3 program for IPF-related chronic cough; first Phase 3 trial to start Q2 2026.
- Cash, cash equivalents $188.3M at year-end 2025; expected runway into 2028.
- Q4 2025 net loss $8.3M vs $11.4M in Q4 2024; FY2025 net loss $42.8M.
- R&D expenses Q4 $6.2M down from $9.3M; G&A $4.0M up from $2.9M.
- Plan to initiate Phase 2b trial for refractory chronic cough in Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526110767/0001193125-26-110767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526110767/trvi-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-110767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer